10/577444

IAP20 Regulativo 27 APR 2006

Docket No.: 3493-0165PUS1 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Jean-Philippe HOULMONT et al.

Application No.: NEW

Confirmation No.: N/A

Filed: April 27, 2006

Art Unit: N/A

For: MEDICAMENT COMP

MEDICAMENT COMPRISING A
REDUCING ALKYL-SUGAR MONOMER

FOR THE TREATMENT OF

INFLAMMATORY DISORDERS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith

Copies of the references on the PTO/SB/08 are not provided.

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or

10/577444

Application No.: NEW

Docket No.: 3493-0165PUS1

AP20 25 27 APR 200

submitted to the Office in a prior application number PCT/FR2004/002798, filed October 29, 2004.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: April 27, 2006

Respectfully submitted,

By H32,88

Mary Angle Armstrong, Ph.D. Registration No.: 40,069

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Road Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.						
Substitute for form 1449A/B/PTO				Complete if Known		
"				Application Number	NEWLY DOOR GALLA	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	April 27, 2006	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Jean-Philippe HOULMONT	
"				Art Unit	N/A	
(Use as many sheets as necessary)			s necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	3493-0165PUS1	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	Τ°
/ESO/	BA**		08-13-1998			
/ESO/			06-12-1998			
/ESO/	BC**	FR-2 768 623-A	03-26-1999			
/ESO/			04-12-1991			
7ESO/	BE**	FR-2 813 789-A	03-15-2002			

**EXAMABET: Initial I reference consistent, whether on not clusten is no coformance with IMED P.600. Draw then through clusten if no in conformance and not consistent. Cluster oxy off his flow with not communicated beganite. "OTER No. Those documentally believe an emaleted with a cluster attention to the CIBs. No are not supplied because they were pervisorly clusted by or submitted to the CIBs. or not supplied because they were pervisorly clusted by or submitted to the CIBs. or not supplied because they were pervisorly cluster than the cluster of the clus

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calatog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
7ESO/	CA**	M. SCHMIDT et al., Chemistry and Physics of Lipids, vol. 114, 2002, pages 139-147.		

*EXAMENEE: Initial Inference considered, whether or not claim is in conformance with MISP 000. There the through citation if not in conformance and not considered. Include copy of the flow with extra communication in age

'Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Eric Olson/	Date Considered	09/25/2008	
D: 1 0:			MAAA/alb	